No data to show
OTCM
ARTHQ
Market cap4kUSD
Jun 05, Last price
0.00USD
Name
Arch Therapeutics Inc
Chart & Performance
P/E
—
P/S
0.07
EPS
—
Div Yield, %
—
Shrs. gr., 5y
32.12%
Rev. gr., 5y
%
Revenues
76k
+383.80%
Net income
-7m
L+63.31%
CFO
-3m
L-24.28%
Earnings
Aug 18, 2025
Profile
Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. The company develops and markets products based on its AC5 self-assembling technology platform to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care or from disease. Its flagship products include AC5 advanced wound system and AC5 topical hemostat, which are intended for skin applications, such as management of complicated chronic wounds or acute surgical wounds. The company was founded in 2006 and is based in Framingham, Massachusetts.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑09 | 2022‑09 | 2021‑09 | 2020‑09 | 2019‑09 | 2018‑09 | 2017‑09 | 2016‑09 | 2015‑09 | |
| Income | |||||||||
Revenues | 76 383.80% | 16 35.34% | |||||||
Cost of revenue | 5,120 | 5,724 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (5,044) | (5,709) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | (1,000) | ||||||||
Tax Rate | |||||||||
NOPAT | (5,044) | (4,709) | |||||||
Net income | (6,983) 63.31% | (4,276) -34.91% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 2,210 | 9 | |||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | 5,628 | 550 | |||||||
Long-term debt | 2,812 | ||||||||
Deferred revenue | |||||||||
Other long-term liabilities | 664 | ||||||||
Net debt | 5,405 | 2,615 | |||||||
| Cash flow | |||||||||
Cash from operating activities | (3,374) | (4,456) | |||||||
CAPEX | (5) | ||||||||
Cash from investing activities | (5) | ||||||||
Cash from financing activities | 2,855 | 2,936 | |||||||
FCF | (3,331) | (3,860) | |||||||
| Balance | |||||||||
Cash | 223 | 747 | |||||||
Long term investments | |||||||||
Excess cash | 219 | 746 | |||||||
Stockholders' equity | (62,051) | (54,823) | |||||||
Invested Capital | 60,171 | 54,656 | |||||||
ROIC | |||||||||
ROCE | 268.33% | 3,423.47% | |||||||
| EV | |||||||||
Common stock shares outstanding | 3,074 | 1,200 | |||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | (5,044) | (5,706) | |||||||
EV/EBITDA | |||||||||
Interest | 3,097 | 567 | |||||||
Interest/NOPBT | |||||||||